CRISIL’s Q1 FY2026 results (January–March 2026) have set a new benchmark for the analytical industry. With a robust surge in both the top and bottom lines, the company has effectively leveraged its global analytical capabilities. While growth is impressive, we maintain our focus on the "cost of growth"—specifically the rising employee expenses that are characteristic of this people-heavy sector.
Profit Explosion: Consolidated PAT surged by 45.9% YoY, far outstripping revenue growth and indicating strong operational leverage and favorable forex gains.
Top-line Momentum: Revenue from operations crossed the ₹1,000 Cr mark for the quarter, growing at a significant 30.1% YoY.
Research Leadership: The Research, Analytics & Solutions (RAS) segment grew by 34.9%, now contributing nearly 70% to the total revenue.
Cost vs. Efficiency:
The company’s efficiency is evident in the PBT growth (35.7%) outpacing Total Income growth (29.6%). This was aided by a significant Forex Gain of ₹14.4 Cr (vs. a loss of ₹5.2 Cr last year). However, we stay critical of the employee costs:
While this is down from previous highs, it remains the single largest "moat-maintenance" cost.
CRISIL vs. ICRA: CRISIL’s revenue scale is now nearly 3x that of its closest listed peer, with a much more resilient global delivery model.
Segment Dominance: While Ratings grew at a healthy 18.9%, the RAS segment's 34.9% growth makes CRISIL more of a "Global Tech-Analytics" firm than just a local rating agency.
Q2 FY26 Guidance: We expect sustained momentum in global risk solutions as banks navigate Basel III endgame regulations.
FY26 Outlook: With India's GDP projected at 7.1%, domestic rating volumes should pick up in H2 FY26 as the capex cycle revives.
Current P/E: ~38x (Trailing)
10-Year Median P/E: 41x
Verdict: Historically Discounted to Fairly Valued.
Despite the recent price rally, the massive jump in PAT makes the stock look more attractive on a trailing basis than it did a year ago.
Promoter Stake: 66.65% (S&P Global).
Pledge: Zero.
Recent Trend: Increased Institutional interest (DIIs) following the consistent 900% dividend payout history.
Strategic Outlook: We view CRISIL as a proxy for both "Global Risk Management" and "Indian Credit Growth." The entry into GenAI-led products like GenEye Credit and DeepMine suggests the company is aggressively moving to protect its margins from talent-cost inflation.
Tactical Outlook: Strong support at ₹4,155 TO 3155. Given the 46% profit jump, the market is likely to re-rate this stock to higher multiples.
Welcome, there!
Your account is active. Enjoy full access.